New combo therapy aims to deepen remissions in Hard-to-Treat myeloma

NCT ID NCT06822972

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remissions. About 27 adults who have already tried at least 4 prior treatments will take selinexor alongside their antibody therapy for up to 12 months. The main goals are to check safety and to see if the combination can make cancer undetectable by a sensitive test (MRD negativity) at 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA REFRACTORY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Duke University Health System
RECRUITING

Durham, North Carolina, 27705, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••